Immune checkpoint inhibitors for the treatment of Tiple-negative breast cancer

Yizhe Shao; Chenziqiu Yang

doi:10.62051/r1g4ph23

Authors

Yizhe Shao
Chenziqiu Yang

DOI:

https://doi.org/10.62051/r1g4ph23

Keywords:

Immune checkpoint inhibitors(ICIs); ICI monotherapy; ICI Combination Chemotherapy

Abstract

Recently, the use of immune checkpoint inhibitors (ICIs) on triple negative breast cancer have been a hot research topic. immune checkpoints are vital as they prevent an immune response from being so strong that it kills healthy cells, which is unwanted. When T cell surface proteins bind to partner proteins (immune checkpoint proteins) on other cells, for instance tumor cells, immune checkpoints engage. When the checkpoint and immune checkpoint protein bind together, a signal is released to prevent the cancer from being killed by the immune system. ICIs work by stopping checkpoint proteins from binding with partner proteins, so the “off” signal was not sent, allowing the immune system to kill the cancer cells. In this review we will focus of the effect of ICI monotherapy, ICI with chemotherapy and ICI with radiotherapy. Results showed that ICI monotherapy, combination of ICIs and chemotherapy, and combination of ICI and radiotherapy have greatly improved ORR, PIS, and OS compared to the traditional chemotherapy. The combination therapy have also revealed a higher cost-effectiveness compared to ICI monotherapy.

Downloads

Download data is not yet available.

References

[1] Akram, Muhammad, et al. “Awareness and Current Knowledge of Breast Cancer – Biological Research.” BioMed Central, BioMed Central, 2 Oct. 2017, Awareness and current knowledge of breast cancer | Biological Research | Full Text (biomedcentral.com) [1]

[2] Yin, Li, et al. “Triple-Negative Breast Cancer Molecular Subtyping and Treatment Progress - Breast Cancer Research.” BioMed Central, BioMed Central, 9 June 2020, Triple-negative breast cancer molecular subtyping and treatment progress | Breast Cancer Research | Full Text (biomedcentral.com) [2]

[3] Li, Yun, et al. “Recent Advances in Therapeutic Strategies for Triple-Negative Breast Cancer - Journal of Hematology & Oncology.” BioMed Central, BioMed Central, 29 Aug. 2022, Recent advances in therapeutic strategies for triple-negative breast cancer | Journal of Hematology & Oncology | Full Text (biomedcentral.com) [3]

[4] Ye, Feng, et al. “Advancements in Clinical Aspects of Targeted Therapy and Immunotherapy in Breast Cancer - Molecular Cancer.” BioMed Central, BioMed Central, 6 July 2023, Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer | Molecular Cancer | Full Text (biomedcentral.com) [4]

[5] Yin, Li, et al. “Triple-Negative Breast Cancer Molecular Subtyping and Treatment Progress - Breast Cancer Research.” BioMed Central, BioMed Central, 9 June 2020, Triple-negative breast cancer molecular subtyping and treatment progress | Breast Cancer Research | Full Text (biomedcentral.com) [5]

[6] Williams, Austin D, et al. “Immunotherapy for Breast Cancer: Current and Future Strategies.” Current Surgery Reports, U.S. National Library of Medicine, Dec. 2017, Immunotherapy for Breast Cancer: Current and Future Strategies - PMC (nih.gov) [6]

[7] Han, Yanyan et al. “PD-1/PD-L1 pathway: current researches in cancer.” American journal of cancer research vol. 10,3 727-742. 1 Mar. 2020 [7]

[8] Buchbinder, Elizabeth I, and Anupam Desai. “CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.” American journal of clinical oncology vol. 39,1 (2016): 98-106. doi:10.1097/COC.0000000000000239 [8]

[9] Kim, Gil-Ran, and Je-Min Choi. “Current Understanding of Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Signaling in T-Cell Biology and Disease Therapy.” Molecules and cells vol. 45,8 (2022): 513-521. doi:10.14348/molcells.2022.2056[9]

[10] Maruhashi, Takumi et al. “LAG-3: from molecular functions to clinical applications.” Journal for immunotherapy of cancer vol. 8,2 (2020): e001014. doi:10.1136/jitc-2020-001014 [10]

[11] Su, Jingjing et al. “Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy.” Frontiers in pharmacology vol. 14 1349081. 10 Jan. 2024, doi:10.3389/fphar.2023.1349081[11]

[12] Nanda, Rita et al. “Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 34,21 (2016): 2460-7. doi:10.1200/JCO.2015.64.8931 [12]

[13] Wesolowski, Jakub et al. “Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer.” Cancers vol. 14,16 3860. 10 Aug. 2022, doi:10.3390/cancers14163860 [13]

[14] Adams, S et al. “Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.” Annals of oncology : official journal of the European Society for Medical Oncology vol. 30,3 (2019): 397-404. doi:10.1093/annonc/mdy517 [14]

[15] Emens, Leisha A et al. “Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.” JAMA oncology vol. 5,1 (2019): 74-82. doi:10.1001/jamaoncol.2018.4224 [15]

[16] Dirix, Luc Y et al. “Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.” Breast cancer research and treatment vol. 167,3 (2018): 671-686. doi:10.1007/s10549-017-4537-5 [16]

[17] Schmid, P et al. “Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.” Annals of oncology : official journal of the European Society for Medical Oncology vol. 31,5 (2020): 569-581. doi:10.1016/j.annonc.2020.01.072 [17]

[18] Chun, Brie et al. “Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer.” Journal for immunotherapy of cancer vol. 10,1 (2022): e004033. doi:10.1136/jitc-2021-004033 [18]

[19] Fasching, Peter A et al. “Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041).” European journal of cancer (Oxford, England : 1990) vol. 184 (2023): 1-9. doi:10.1016/j.ejca.2023.01.001 [19]

[20] Cortes, Javier et al. “Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.” BMC cancer vol. 23,1 792. 23 Aug. 2023, doi:10.1186/s12885-023-11293-4 [20]

[21] Lynce, Filipa et al. “Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.” medRxiv : the preprint server for health sciences 2023.12.04.23297559. 4 Dec. 2023, doi:10.1101/2023.12.04.23297559. Preprint. [21]

[22] Ademuyiwa, Foluso O et al. “A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013.” NPJ breast cancer vol. 8,1 134. 30 Dec. 2022, doi:10.1038/s41523-022-00500-3 [22]

[23] Wu, Bin, and Fei Ma. “Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer.” Therapeutic advances in medical oncology vol. 12 1758835920916000. 5 May. 2020, doi:10.1177/1758835920916000 [23]

[24] Ho, Alice Y et al. “A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer.” Cancer vol. 126,4 (2020): 850-860. doi:10.1002/cncr.32599 [24]